Novel therapeutic strategy against multidrug-resistant gram-negative bacteria [ 2006 - 2008 ]

Also known as: New therapy for gram-negative superbugs

Research Grant

[Cite as]

Researchers: Prof Jian Li (Principal investigator) ,  Dr Craig Rayner Prof John Turnidge Prof Roger Nation

Brief description In the past two decades, there has been a marked decline in discovery and development of new antibiotics while there has been a remarkable increase in resistance to the currently available antibiotics. The growth in the number of resistant bacteria and lack of antibiotics available for treatment is very significant with gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Colistin, an old antibiotic that has been used little over the last 40-50 years, has been 'taken off the shelf' and is now being used as a last line of defence to treat people with infections caused by these bacteria. Clearly, doctors and their infected patients will be in an even more precarious position than currently exists if resistance to colistin increases. We have discovered a novel therapeutic strategy that is able to reverse colistin resistance in P. aeruginosa. The studies proposed in this project will investigate this novel strategy across a range of multidrug-resistant bacteria and provide the information essential for rational use in patients. We propose that such a novel therapeutic strategy will provide a powerful weapon for the war on these 'superbugs'.

Funding Amount $AUD 349,823.48

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]